Geron: Minimal Sales Growth But A Potential Run-Up Ahead (NASDAQ:GERN)

Geron Corporation ( GERN ) could have multiple clinical readouts in 2026, serving as a potential catalyst beyond how the company performs commercially with Rytelo (imetelstat). When I last wrote about GERN in January, I rated the name aScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I ...